RT Journal Article
T1 Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer
A1 Morales, Paula
A1 Blasco-Benito, Sandra
A1 Andradas, Clara
A1 Gómez Cañas, María
A1 Flores, Juana María
A1 Goya, Pilar
A1 Fernández-Ruiz, Javier
A1 Sánchez, Cristina
A1 Jagerovic, Nadine
AB Triple-negative breast cancer (TNBC) represents a subtype of breast cancer characterized by high aggressiveness. There is no current targeted therapy for these patients whose prognosis, as a group, is very poor. Here, we report the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer designed as a combination of quinone/cannabinoid pharmacophores. This new compound (10) has been selected from a series of chromenopyrazole diones with full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death of human TNBC cell lines. The dual concept quinone/cannabinoid was supported by the fact that compound 10 exerts antitumor effect by inducing cell apoptosis through activation of CB2 receptors and through oxidative stress. Notably, it did not show either cytotoxicity on noncancerous human mammary epithelial cells nor toxic effects in vivo, suggesting that it may be a new therapeutic tool for the management of TNBC
PB Journal Medical Chemistry
SN 0022-2623
SN 1520-4804
YR 2015
FD 2015
LK https://hdl.handle.net/20.500.14352/93638
UL https://hdl.handle.net/20.500.14352/93638
LA eng
NO Morales  P, Blasco-Benito  S, Andradas  C, Gómez-Cañas  M, Flores  JM, Goya  P, Fernández-Ruiz J, Sánchez C, Jagerovic N. Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer. J MedChem. 2015, 58(5):2256-64.
DS Docta Complutense
RD 19 abr 2025